Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- cardiac
- Disease
- Enzymes
- Therapeutic
- Pharmaceuticals
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 260445
With the First Amendment to the License Agreement under which Licensee granted to Licensor the right to co-market the Product containing the oral form of Enoximone (Oral Enoximone) in Europe. This grant was terminated under the Second Amendment to the License Agreement.
The Second Amendment provided for a certain royalty to be paid by Licensee to Licensor in the event the Net Sales of Oral Enoximone in Europe reached or exceeded the threshold set forth in the amendment.
Licensor was acquired by a pharmaceutical company organized under the laws of France.
The Parties acknowledge and agree that the License Agreement only obligates Licensee to pay Licensor royalties on Net Sales of Perfan i.v. in the Limited European Countries. The Agreement does not obligate Licensee to pay royalties on the Net Sales of Oral Enoximone in the Limited European Countries. The Parties further acknowledge and agree that the License Agreement, as amended and restated, only concerns and relates to the sale of any Product, including Perfan i.v. and Oral Enoximone, in any Territory other than Europe, and only concerns and relates to the sale of any Additional Product in the Limited European Countries.
Licensor transfer of the Licensor Trademarks in the United Kingdom and the Benelux countries of Belgium, the Netherlands and Luxembourg, is perpetual and irrevocable, as of the Effective Date of the Third Amendment.
Perfan® I.V. is an intravenous (i.v.) formulation of enoximone.
IPSCIO Record ID: 263953
For Commercialization, Licensor grants an exclusive, even as to Licensor and its Affiliates, license under the Licensor Patents and Licensor Know-how to conduct manufacturing, pre-marketing activities, commercialization, including the right to make, have made, use, import, sell, offer for sale and have sold, and related activities in the Territory with respect to Enoximone and any Product in accordance with the terms of this Agreement.
Licensor Patent means any and all Patents which cover the discovery, evaluation, manufacture, use or importation, offer for sale and/or sale of Enoximone in the Field or Product, which Patent is owned or Controlled by Licensor or any of its Affiliates, including Licensors or any of its Affiliates interest in any Joint Patent.
Enoximone is a small organic molecule that exhibits highly selective inhibition of type-III phosphodiesterase, or PDE-III, an enzyme that is present in the heart and plays an important regulatory role in cardiac function.
TITLE ENHANCEMENT OF PRAZOSIN
ABSTRACT THIS INVENTION RELATES TO THE SYNERGISTIC ENHANCEMENT OF CERTAIN ANTIHYPERTENSIVES BY THE CONJUNCTIVE USE OF CERTAIN CARDIOTONIC AGENTS. MORE SPECIFICALLY, THIS INVENTION RELATES TO THE ENHANCEMENT OF THE BLOOD PRESSURE LOWERING EFFECT ACHIEVED WITH ALPHAl-ADRENOCEPTOR ANTAGONISTS BY THE CONJUNCTIVE ADMINISTRATION OF CARDIOTONIC AGENTS POSSESSING THE ABILITY TO SPECIFICALLY
IPSCIO Record ID: 240469
The licensed property is Angiotensin-converting enzyme genetic variant screens; Transgenic model and treatment for heart disease; Transgenic Model for Heart Failure; Method for identifying adrenergic receptor antagonists having good tolerability; Diagnosis and treatment of myocardial failure; Method of treating heart failure; Inhibition of HDAC as a treatment for cardiac hypertrophy; and, Quantitative analysis of closely related protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry.
IPSCIO Record ID: 28537
SubLicensor has obtained in a separate license agreeement an exclusive worldwide License (patents and know-how) to develop and commercialize Enoximone and all of rights under certain existing trademarks relating to Enoximone in several countries around the world.
Know-How License to Sublicensee for Commercialization. Upon the terms and subject to the conditions of this Agreement and the License Agreement, including, without limitation, the payment obligations herein, SubLicensor grants to Sublicensee an exclusive (even as to SubLicensor and its Affiliates) license under the SubLicensor Know-How to conduct Manufacturing, pre-marketing activities, Commercialization (including the right to make, have made (subject to Article 2.3), use, import (subject to Article 2.3), sell, offer for sale and have sold) and related activities in the Territory with respect to the Product in accordance with the terms of this Agreement.
Know-How License to Conduct Regulatory Approvals. Upon the terms and subject to the conditions of this Agreement and the License Agreement, including, without limitation, the payment obligations herein, SubLicensor grants to Sublicensee an exclusive license (even as to SubLicensor and its Affiliates) under the SubLicensor Know-How to conduct the Regulatory Approvals in the Territory in accordance with the terms of this Agreement with respect to the Product for use in the Field.
'Product' means that intravenous formulation of Enoximone for use in the Field marketed under the Trademarks. 'Enoximone' means 1,3-dihydro-4-methyl-5-[4-(methythio)-benzoyl]-2H-
imidazol-2-one, and all pharmaceutically-acceptable forms (e.g., salts) and all formulations thereof.
Enoximone is a small organic molecule that exhibits highly selective inhibition of type-III phosphodiesterase, or PDE-III, an enzyme that is present in the heart and plays an important regulatory role in cardiac function.
